Craig-Hallum downgraded Avadel Pharmaceuticals (AVDL) to Hold from Buy with a $20 price target after the company agreed to be acquired by Alkermes (ALKS) for for $18.50 per share upfront along with a non-transferable contingent value right entitling holders to a potential additional cash payment of $1.50 per share.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVDL:
- Alkermes enters sleep space at attractive price, says H.C. Wainwright
- Hold Rating for Avadel Pharmaceuticals Amidst Upcoming Acquisition and Market Complexities
- Avadel Pharmaceuticals downgraded to Hold from Buy at Jefferies
- Avadel Pharmaceuticals Acquired by Alkermes for $2.1 Billion
- Avadel Pharmaceuticals downgraded to Hold from Buy at Needham